Company intelligence / Profile preview
Andira Pharmaceuticals
Vancouver, British Columbia, Canadaandira.ca ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Andira has completed pre-clinical safety studies for Silvanex™ Flex and is advancing toward clinical trials. Their lead products include Matrix3™ Shield for surgical site infection and a triple synergy antibiotic technology. As of May 2025, they are approximately one year away from entering Phase 1 clinical trials.
- Therapeutic areas
- OncologyDermatologyInfectious Diseases
- Modalities
- Small molecule drugsCannabinoid-based therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
US Capital Globalacademic institutions and research hospitals (specific names not provided)
Beyond the preview
Go deeper on Andira Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Andira Pharmaceuticals.